Floatz logo

Palifermin

Recurrent Mycosis Fungoides/Sezary Syndrome

Martin, Paulprotein_peptideN/ADormant
D
30/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
15/ 100
Competitive Position
95/ 100

Competitive context

51 Active assets in the Recurrent Mycosis Fungoides/Sezary Syndrome cohort.

Asset / SponsorPhaseRating
(+)-VINCRISTINE
Virogen Biotechnology Inc.
Phase 4BBB
Cyclophosphamide
National Cancer Institute (NCI)
Phase 4BBB
Fludarabine
National Cancer Institute (NCI)
Phase 2BBB
FILGRASTIM
Mayo Clinic
Phase 4BBB
METHOTREXATE
Polish Lymphoma Research Group
Phase 4BBB

View all 50 →

Same molecule, other indications

Palifermin is also rated in:

mucositisDormant
BB
Indicative ·
64 / 100
View asset →
non-Hodgkin lymphomaDormant
B
Indicative ·
63 / 100
View asset →
plasma cell myelomaDormant
B
Indicative ·
61 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →